Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic pineal-derived tetrapeptide / AEDG peptide
An experimental peptide often discussed for aging, sleep rhythms, and longevity.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 25, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
One limited human circadian-biomarker report with essential design details missing from the indexed abstract
It is a four-amino-acid peptide. Epithalamin is a different bovine pineal extract and should not be treated as the same intervention.
This is the clearest located human signal for synthetic AEDG, but it measured biomarkers—not sleep quality, lifespan, or clinical anti-aging outcomes.
Two laboratory papers reported telomere-pathway effects, including a 2025 study in normal and cancer cell lines.
That unexpected cancer-cell finding is a research uncertainty, not evidence that Epithalon prevents or treats cancer.
Fruit-fly and transgenic-mouse studies reported lifespan or tumor signals, but no controlled human longevity or cancer-prevention trial was located.
Researchers have measured oxidative-stress, wound-closure, and neurogenic-marker changes in models, not demonstrated patient benefit.
The human record is far thinner than many online summaries imply, and results involving Epithalamin extract cannot automatically be assigned to synthetic Epithalon.
FDA records the chemical identity of Epitalon, but no approved U.S. drug product or indication was located.
FDA specifically cites possible aggregation and peptide-related impurities and says it lacks enough information to know whether the drug would cause harm.
Cell concentrations and animal exposure schedules are experimental details, not instructions for people.
Risks & unknowns
FDA says compounded Epitalon may pose immunogenicity and impurity risks and that safety information for proposed human routes is insufficient.
No direct evidenceThe FDA entry identifies uncertainty and potential risk; it is not an adverse-event incidence estimate.
Open sourceFDA says compounded Epitalon may pose immunogenicity and impurity risks and that safety information for proposed human routes is insufficient.
No direct evidenceThe FDA entry identifies uncertainty and potential risk; it is not an adverse-event incidence estimate.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Human biomarker reports exist, but the reviewed accessible source does not verify a complete administered Epithalon regimen. Epithalamin extract and cell-culture concentrations are different evidence.
What would fill this gap: Primary methods identifying synthetic AEDG, amount, route, frequency, and duration.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A published human report examined circadian-related biomarkers after AEDG peptide exposure in middle-aged people with reduced pineal melatonin-producing function.
Population: Middle-aged people with reduced melatonin-producing pineal function
Design: Human biomarker report; design details incomplete in the indexed abstract
Mechanisms
Epithalon, also called Epitalon or AEDG, is the tetrapeptide Ala-Glu-Asp-Gly. A limited Russian-language human report described changes in urinary 6-sulfatoxymelatonin and circadian-gene expression, but the indexed abstract omits essential design and safety details. Laboratory studies report telomerase-related activity, telomere elongation, oxidative-stress effects, retinal-cell wound closure, and neurogenic-marker expression. Animal and insect studies report lifespan and tumor-related signals. A corrected 2025 study also found ALT-associated telomere lengthening in breast-cancer cell lines, which is an unresolved safety-relevant uncertainty. No robust controlled human anti-aging or longevity trial and no FDA-approved product were located.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
The direct record includes cell and animal studies plus one limited human circadian-biomarker report with essential protocol details missing.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
No robust controlled human trial demonstrates longer life, better sleep, telomere benefit, disease prevention, or route-specific safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The abstract omits sample size, allocation, comparator, route, exposure pattern, adverse events, and clinical sleep outcomes. The record cannot establish improved sleep, slower aging, longer life, or a transferable administration pattern. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
In-vitro dose-response study in two normal and two breast-cancer human cell lines
Normal epithelial and fibroblast cells plus 21NT and BT474 breast-cancer cells
Telomere length increased in normal and cancer cell lines. Normal cells showed telomerase-related changes, while cancer cells showed ALT-pathway activation.
Study administration: Epitalon at laboratory concentrations from 0.1 to 1 microgram/mL
Limitations: This was a corrected 2D cell-culture study, not a human trial. The cancer-cell finding creates uncertainty rather than proving safety, cancer prevention, or healthy-longevity benefit.
In-vitro high-glucose injury and scratch-wound assay
ARPE-19 human retinal pigment epithelial cell line
Epitalon improved closure and several oxidative-stress and fibrosis markers in the cell model.
Study administration: Epitalon added to high-glucose-injured cultured cells
Limitations: This was not a patient study and does not demonstrate prevention or treatment of diabetic retinopathy, vision benefit, a human route, or ocular safety.
In-vitro gene and protein-expression study with molecular modelling
Human gingival mesenchymal stem cells
Neurogenic marker expression increased in cultured stem cells, and modelling suggested possible histone interactions.
Study administration: AEDG peptide exposure in cultured cells
Limitations: Marker changes in cells do not demonstrate brain repair, cognition, neuroprotection, or clinical neurologic benefit.
Human biomarker report; design details incomplete in the indexed abstract
Middle-aged people with reduced melatonin-producing pineal function
The abstract reports a 1.7-fold increase in urinary 6-sulfatoxymelatonin, lower Clock and Csnk1e hyperexpression, and higher Cry2 expression.
Study administration: AEDG peptide exposure; route, schedule, dose, comparator, and allocation were not reported in the PubMed abstract
Limitations: The English abstract does not report sample size, control group, allocation, route, dose, duration, adverse events, or clinical sleep outcomes. It cannot establish improved sleep, anti-aging benefit, or a usable protocol.
In-vitro human fetal fibroblast culture experiment
Telomerase-negative human fetal fibroblast cells
The paper reported telomerase expression and activity plus telomere elongation in cultured fibroblasts.
Study administration: Epithalon added to cultured cells
Limitations: A cell-culture finding is not evidence that Epithalon lengthens telomeres, slows aging, extends life, or is safe in people.
Lifelong exposure experiment in a transgenic breast-cancer mouse model
Female FVB/N mice carrying HER-2/neu
The study reported longer average and maximum lifespan and fewer tumor outcomes in this specific mouse model.
Study administration: Protocol-defined subcutaneous Epithalon exposure five times weekly
Limitations: A transgenic mouse experiment cannot establish cancer prevention, treatment, anti-aging benefit, or safety in humans. Lifelong animal exposure is not a human protocol.
Developmental-exposure lifespan experiment in fruit flies
Male and female Canton-S Drosophila melanogaster
Adult lifespan was reported to increase by 11% to 16%, without a clear dose-response relationship.
Study administration: Epitalon added to fly culture medium at experimental concentrations
Limitations: Fruit-fly developmental exposure does not establish human lifespan extension, a human dose, route, cycle, or long-term safety.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2025-09-04 · PMID 40908429 · DOI 10.1007/s10522-025-10315-x
2025-06-10 · PMID 40493162 · DOI 10.1007/s12015-025-10911-x
2025-03-17 · PMID 40141333 · DOI 10.3390/ijms26062691
2020-01-30 · PMID 32019204 · DOI 10.3390/molecules25030609
2020-01-01 · PMID 33280326
2007-01-01 · PMID 17317455 · DOI 10.1016/j.archger.2007.01.029
2003-06-01 · PMID 12937682 · DOI 10.1023/A:1025493705728
2002-08-01 · PMID 12459848 · DOI 10.1023/A:1021104819170
2000-12-01 · PMID 11087911 · DOI 10.1016/S0047-6374(00)00217-7